This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Joint Stock Company "Biocad". Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Anna Valentinovna Evstrateva: Innovator in Monoclonal Antibodies
Introduction
Anna Valentinovna Evstrateva is a prominent inventor based in Pitkyaranta, Russia. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 2 patents, her work focuses on innovative treatments for diseases associated with the human T cell receptor family.
Latest Patents
Evstrateva's latest patents include groundbreaking inventions related to monoclonal antibodies that specifically bind to the TRBV9 family of the human T cell receptor. One of her notable patents describes a monoclonal humanized antibody or antigen-binding fragment that targets the TRBV9 family. This invention encompasses a nucleic acid encoding the antibody, an expression vector, and methods for preparing the antibody. The applications of this antibody are particularly relevant for treating diseases such as ankylosing spondylitis, celiac disease, and malignant blood diseases, which involve the TRBV9 family T cell receptors. Another patent focuses on monoclonal antibodies against the beta chain region of human TRBV9, further emphasizing her commitment to advancing therapeutic options in immunology.
Career Highlights
Evstrateva is currently associated with Joint Stock Company "Biocad," where she continues her research and development efforts. Her work has positioned her as a key figure in the biotechnology sector, contributing to the advancement of medical treatments through innovative antibody therapies.
Collaborations
Throughout her career, Evstrateva has collaborated with notable colleagues, including Roman Alekseevich Ivanov and Dmitry Valentinovich Morozov. These partnerships have enhanced her research capabilities and broadened the impact of her inventions.
Conclusion
Anna Valentinovna Evstrateva is a trailblazer in the field of monoclonal antibodies, with a focus on innovative treatments for serious health conditions. Her contributions to biotechnology are paving the way for new therapeutic approaches that could significantly improve patient outcomes.